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J.J. Crowley, P.ConIon, R.M. Santos, H.R. Phillips, R.S. Stack. Duke
University Medical Centec Durham, NC, USA
Ieohemic renal disease caused by renal artery stenosis (RAS) isa potentially
treatabla condition. However, the role of intervention for RAS not associated
with hypertension or decreased renal function has not been eatsblished. In
this study we assessed the effect of RAS on renal function in 1015 consecu-
tivepetienta (maan age60+ 11yeara)whoundervventcardiaccatheterization
and abdominal aortography on ?2 occaaions at least 6 months apart (mean
2.6 + 1.7 yeare). All patients had normal renal arteries at baseline.
Resu/ts;219 patients (21.6%) had ?25%stenosis of at least 1 renal artery
at follow-up.
“ARAS n Creatinine(m@dL)
Baseline o 1015 1.07 + 0,27
Follow-uP o 798 1,12 + 0,60
25 99 1,17 * 0,64
50 62 1,10 + 0.33
75 29 1,23 + 0.40
:95 29 1.90 + 1.81’
*p= 0.03 compared to othergroups
After excluding patients with significant (>50%) contralaterel RAS, follow-
UPcreatinine (1.69 + 1.66 mg/dL) remained significantly elevated when RAS
was ?95% (n= 27, p = 0.04).
Conclusions: Progression of RAS to ?95% is associated with a signifi-
cant deterioration in renal function. Elevation in serum creatinine may occur
despite insignificant diaease in the contrelateral renal artery.
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P.C. Deedwania, G. Wine, E.E. Carbajal, J. Guernsey. VAMC/UCSFSchoo/
of Medicine, Fresno, CA, USA
Although multi-vessel CAD patients (pts) are frequently referred for myccar-
dial revaacularization (revasc) before peripheral vascular surgery (PVS) in
hope of reducing risk of cardiac events, little data are available to support
routine use of revasc before PVS. In a prospective study we evaluated the
safety and ( of long-acting PI selective beta-blocker, betexolol (B),
in @ucing risk of perioperative cardiac events. Ischemia was evaluated by
exerciae stress testing, Helter monitoring (HM) and dipyridamole thallium
acintigraphy. Patients with evidence of ischemia underwent angiography.
Those with ischemia and multivessel CAD (excluding left main or 3V with
LVEF < 40%) were titrated on B 10-20 mg qd for 2 wks prior to PVS. All
pta were carafully evaluated for Ml, unstable angina, shock, and serious
arrhythmias during the perioparative period. Resu/ts:34 pts underwent PVS.
24 pts received B, 10 pts not receiving B served as controls.
E C
Age, Mean ISD 66*5 67& 2
SyatolicBP.* 136 *23 132 +17
DiastolicB.P” 67* 10 77% 12
Heart Rste* 60+8 61 h 22
EjectionFraction 59 h 8 57+ 6
CAD (Svesaala) 2,3 2
% CV eventa o 30
Comparison of preoperative hemodynamic values (*) revealed that pts
on B had significantly (p c 0.05) lower mean HR and lower diastolic BP.On
repeat HM, ischemia was suppressed in 70% of pts on B. Although 30% of
the control group had CV events, none of the B pts had any cardiac event X2
= 3.94, p = 0
Conclusions: d b effective in sup-
pressing myooerdial ischemia and reduces perioperative CV events in pa-
tients with multivessel u
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M M L Cardiovascular Department, Sandoz
PE Milan, Italy, Biometrics Department, Sandoz PE Mi/an, Italy
In patients at high cardiovascular risk, concomitant hypercholesterolemia
(HC) may reduce the protective effect of antiplatelet drugs such as aspirin
or ticlopidine. Picotamide (Pico) is an orally active antiplateiet agent which
inhibits thromboxane (Tx) A2 synthesis and antagonizes Tx receptors. The
ADEP (Atherosclerotic Disease Evolution by Picotamide) trial had evaluated
the effects on cardiovascular evants of pico, In comparison to placebo, in
2313 patientswith peripheral occlusive vascular disease (POVD). Intheetudy
Population as a whole, Pico reduced c 19% (P=
Logrank test). We conducted, in an “a priori” planned hypotheaia,a eubgroup
analysis to assess the influence of concomitant HC on the protective effect
of pico on cardiovascular events in POVD patients. The efficacy of pioo
was therefore assessad in the ADEP subgroup of HC patients in order to
test if the drug was still effective in this higher risk group. HC was defined
se a serum total cholesterol (TC) greater than 5.2 mmol/L, measured at
baee-lina. In pico treated group, HC patienta were 763 whereaa 262 were
the patients with a TC c 5.2 mmol/L. During the 16-month of follow-up,
there were 76 (9.9%) cardiovascular events (death, myooardial infarction,
stroke, TIA, unstable angina and amputation) in the 763 HC pico-treated
patients as compared to 140 (13.1%) events in the 1066 placebo-treated
subjects (Relative Risk Reduction: 27%, P = 0.03, Mantel-Haenszel Chi-
Square test). In pico-treated patients, no statistical significant difference
on cardiovaeoular event rate were observed among normo and HC patients
(10.6% and 9.9%, respectively). In POVD patients pico effectively reduced
cardiovascular events, irrespective to serum TC levels.
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Kharbanda, N. Haider, P. Pandey, G.W. Dee, M. Semigren, J.L. Gurero,
B.-A. Khaw, R. Virmani, R. Davis, D. Kufe, J. Narula. Dana-Farber Cancer
Institute and Masaechusetts General Hospital, Boston, MA, USA
Brief repetitive episodes of myocardial ischamia, often asymptomatic and not
resulting in significant myocyte necrosis, are the commonest manifestations
of coronary artery disease (CAD). Mammalian cells, in responae to ischemia,
expressa variety of genes to adapt to external stress or inflict further damage.
To evaluate intracellular signaling cascade involving the SAP/JNK kinase in
response to brief episodes of ischemia, LAD coronary artery was occluded
for 5-60 min in rats. SAPk activity (assessed by in vitro immune complex
kinase assays using GST-Jun) increased from 5-10 rein, reached maximum
at 15 min and decreased significantly by 30-60 min. Upon reperfusion after
15 min LAD ligation, the maximal levels of SAPkacfivity were sustained up to
60 min. SAPk induction was also confirmed in neonatal rat myocytea aa well
as H9C2 embryonic rat cerdiocytas. To evaluate sequence of hypoxic SAPk
indur3ion, H9C2 cells were cotransfected with pEBG-SAPk and dominant-
negative mutants (DNM) of SEKI (SEK1 K + R). SEKI K -+ R completely
abrogated SAPk induction. DNM of Racl (N17) and PAK1 with pEBG-SAPk
also inhibited SAPk activation confirming the role of Racl/cdc42Hs and STE-
20 homologies in hypoxic insult to oerdiomyccytes. No activation of MAP or
P-38 MAP kinasa was observed in response to hypoxia.
Cone/usions:The immediate-early activation in brief episodes of myooar-
dial ischemia in CAD may play a role in long-term deleterious effects through
abnormal myocerdial growth response or occurrence of apoptosis. Further,
elucidation of upstream activators of SAPk may help develop intervention
strategies.
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M. Arai, S. Minatoguchi, G. Takamura, Y. Uno, T. Kariya, T. Fujiwara,
M. Higashiokal, Y. Yoshikuni1, H. Fujiwara. Gifu University Schoo/of
Medicine, Gifu, Japan, 1>Nippon Shinyaku Co., Ltd., Kyoto, Japan
Ischemic preconditioning has a marked infarct siza-reducing effect in hearts.
Pre-ischemic glycogen reduction or glycogenolyfic inhibition may be one of
the mechanisms. Itwas speculated that the compound reducing glycogenolytic
rate by inhibiting a-l ,6-glucosidase of glycogen debranching enzyme in
liver, MOR-14 (N-methyl-l -deoxynojirimycin), may precondition pharmaco-
logically the heart. Thus, it was investigated whether MOR-14 inhibits a-l,6-
glucosidase also in the heart and reduces the infarct size in rabbit hearts
without collateral circulation.
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Methods: Rabbita were randomized to receive 100 mgikg of MOR-14
or an equivalent volume of saline 10 min before iachemia. Infarct size was
aaesssad by TTC at 48 hr of repeffusion following 30 min ischemia and was
expressad as a percent of area at riak (lN/AAR) (MOR-14: n = 10, saline: n =
10). a-1,8-glucosidase activity (pmol glucose incorporated into glycogen per
min per mg protein), and glycogen and lactate content (mglg tissue) in the
ischemic myocardium were assesaed at 30 min of ischemia (MOR-14: n =
11,saline: n = 11).
Resufts: Date are given below.
IN/AAR(%) a.1,6-Glucosidsse Glycogsn Lactate
MOR-14 14& 2* 1.7 * 0.2” 1.3 * 0.1” 2.6 + 0.2”
Saline 45* 5 7.s * 1.4 0.4 * 0.1 3,9 * 0.2
(mean + SEM, “p <0.05 vs. saline)
Cone/usions:Pre-ischemic treatment with MOR-14inhibited cel,6-glucosidase
activity in the heart, presewad the glycogen content, attenuated the Iactata
accumulation, and reduced the infarct size by 69Y0 without affecting the
hemodynamice or regional blood flow. The compound will be useful forphar-
macologicsl preconditioning againat iachemia.
988-95 Antimyosin Immunoliposomes Prevent and
Reverse Cardiocyte Death Induced by Hypoxia up
to 5 Days
1.Vural, J. Narula, V. Torchilin, B.-A. Khaw. Northeastern University and
Massachusetts Geneml Hospital, Boston, USA
Antimyoain-immunoliposomes (IL) have been shown to presewe cerdio-
cyte viability by sealing hypoxia-induced aarcdemmal lesions. To determine
whether protection can be extendad to longer periods of hypoxia, H9C2 rat
cardiocytas (2 x Id) in culture were subjected to hypoxia for 1-5 days with
IL and plain Iiposomea (PL). The cell viability of cardiocytea asaessad by
3H-Thymidine (3HT) upfake was compared with hypoxic controls (HC) and
cells cultured in normoxic condition (NC). After 24 H, viability of NC cells
(254 + 18%) waa similar to H9C2 hypoxic cella treated with IL (225 + 13%).
Viability of 24 h hypoxic cells treated with PL (9– + 13%) or HC (- O%)was
significantly lower. Viability of IL treatad cells at 2, 3,4 and 5 days waa 89 +
12, 49 ~ 8, 15 + 8 and 8 + 4%, respectively, campered to 4 + 1, 1 + 0.2,
0.2 +0.1 and 0.5 + 0.4% of PL treated calls. Since 3HT uptake of IL-treated
hypoxic cells increased by 250% aimilarto NC cells, ILtreatment must allow
the csrdiocytes to continua call replication aven under severe hypoxia.
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Thia study shows the potential of IL-based aalvage of ischemicelly com-
promised myocardial cella.
1988-96[ Monoclinal AntibOdyto C5inhibits C5a And C5b-9
Generation Without Inhibition of C3 Cleavage and
Significantly Limite Myocardial Iechemia and
Reperfusion Induced Tiasue Damage
A. Vakeva, S.A. Rollina, L.A. Matis, G.L. Stahl. 6rfgham and Women’s
Hospital, Boston, MA, USA, Alexion Pharmaceuticals, New Haven, CX USA
The role of early (C3a, iC3b) vs late (C5a, C5b-9) complement components
in myocerdial ischemiaheperfusion (MVR) injury has not been established.
In order to eeeees the contribution of C5a and C5b-9 in a ret model of
Mi/R injury, monoclinal antibodies (Mab) were reiaed againat rat C5 and
characterized. Mabl or Mab2 bound ret C5, but only Mabl blocked C5a
and C5b-9 generation. In a rat model of myocerdial ischemia (34 rein) and
rep#usion (4 hre), pretreatment with Mabl (n =4; one hr bafora iachemia)
aignificently (p c 0.05) prevented left ventricular free wall (LVFW) creatine
phoaphokinase loss compared to PBS (n =5) or Mab2 (n =5) treated rate
(–0.4 & 1.1 VS3.9 + 1.0 or 4.5 + 0.9 ILJ/mgprotein, respectively). PMN
infiltration into the LVFW was significantly (p < 0.05) inhibited in Mabl -
treatad rats compared to PBS or Mab2 treatad rats (0.2 + 0.2 vs 2.7 +
0.8 or 2.2 + 0.8 U MPO/g wet weight, respectively). Mabl treatment 1 hr
before ischemia (n = 4) or 5 min before reperfusion (n = 8) significantly
(p < 0.05) reduced infarct size (TTC staining; infarct area:area at risk x
100) mmpsrad to PBS (n = 5) or Mab2 (n = 3) treated rats (25 + 6 or
38 + 7 va 76 & 7 or 72 + 4%, respectively). Mabl (n = 5) treatment in
rate undergoing mymardial ischemia (4 hre) and no repedusion significantly
(p < 0.05) reduced infarct size compared PBS (n = 6) treatment (57 + 7
va 94 + 2%, respetiively). Immunohistochemistry demonstrated significant
C3 deposition in treated and untreated hearts. These data suggest that
C5p and C5b-9 are the predominant complement mediators of myocerdial
ischemie/repsrfusion injury. Further, these data suggest that mmplement
inhibition at C5, which presewes the immunoprotactive effects of C3b and
blocks the proinflammatory effects of C5a and C5b-9, may represent a
potentially effective therapeutic intervention for myocardial iachemia and
reperfusion injury.
1988-971 C$rdiOprotectiofl bytheAT,-Rdceptor Blocker
Loastten is Dependent on Bradykinin Receptor
Activation
P.T.Buser, P.Zhu, P. Hornatein, P.R.Allegrini, C.E. Zaugg. Division of
Cardiology University Hospita/, Base/, Swifzer/and
Cardioprotaction of ACE inhibitore in the ischemic and reperfused rat heart
are mainly mediated by bradykinin receptor activation. In recent studies,
Iosartan (Los) - an AT1 receptor blocker – apperantly had no effect on
the brsdykinin system. The aim of this study was to define whether 1)
Loa exerts cardioprotectiva effects during ischemia and reperfusion, and
whather 2) these effects are dependent on bradykinin receptor activation.
In the Langendorlf rat heati, coronary flow (CF), left ventricular developed
preesure (LVP) and the high energy phosphates phosphocreatin (PCr) and
b-adenoain-triphosphate (ATP) by 31phosphoruamagnetic resonance epac-
troscopy were monitonxf during 15 min ischemia and 30 min reperfusion.
Relative changes of the variablea were compared between untreated hearts
(Ctr), hearta treatad with 10-7 M ramiprilat (Ram), 10-8 M Los and the com-
bination of 10-7 M Hoe-140 (Hoe) - a bradykinin receptor antagonist - with
Ram or Los. Compared to baseline values, percent recovery was:
Grmm CF 1%) LVP (“A) PCr (“A} ATP P/o)
Ctr(n = 7) 47+ 3 3s+7“ ’63 * 7 47* 5
Ram (n= 7) 73+ 5* 78+ 6* 107 * 11* S2* 7*
Los(n =7) 66 +3” 81 & s“ 97& 4* 63 i S*
Ram + Hoe (n = 6) 39 i P 13* 3** 34+ llg” 44k 6#
Los+ Hoe (n= 7) 52& 6$ 2s k e# 64 i 5# 50 *#
Mean + SEM, *p <0,05 vs. Ctr, $ p <0.05 vs. conditionwithoutHoe
Los improved postischemic recove~ of CF, LVP, PCr and ATP. Thie was
comparable to the effects of RAM. When combined with Hoe, the cardiopro-
tective effacte of both Los and Ram were aboliahad. Thua, in the rat heart,
Losexedscsrdioprotective effectsduring ischemiaand repetiusion and these
effects are dependent on unrestreined bradykinin receptor activation.
-~ Adeno$if’ieMediat$$ tha,nfarctSi.eLimiting ~ff.ct
of Magnesium in Rabbite
T. Matsuzeka, N. Hasebe, T. Fujino, A. Ido, S. Natori, H. Nakamura,
H. Matsuhashi, K. Kikuchi. Asshikawa Medical College, Asahikawa, Japan
Intravenous magneaium (Mg) therapy haa been reported to reduce mortality
in acute myocsrdial infarction, but the exact mechanism is unknown. The
objsctivea of the present study were to determine whether Mg treatment
can limit myocerdial infarct size (IS), and if so, whether the mechanism is
mediated by endogenous adenosine, a major cardioprotective substance in
ikchemic myocardium.
Four groups of Japanese white rabbits underwent 30 min coronary attery
occlusion (CAO) and 3 hr repeflusion (CAR). Aortic pressure and ECG
were continuously monitored throughout the experiment. (l): Control group
C was untreated. (2): 8PT (6-phenyitheophylline, a broad acting adenoaine
receptor antagonist) group received 6PT (10 mg/kg bolus iv) 25 min before
CAO. (3): Mg group was pre-treated with magnesium sulfate (1 mglk~min
iv) for 30 min before GAO followed by a maintenance dose of Mg (0.14
m@@min) throughout CAR. (4): Mg + 8PT group was given both agents.
Systemic hemodynamice and the incidence of ventricular arrhythmia were
not significantly affected by Mg. Tetrazolium was usad to stain the infarct
area. E/area at risk (AR) ratios were then calculated.
Group c Mg 8PT Mg+SPT
%18/AR 49& s 24+ 11* so* 9 43* 9
*p <0.05 Vsc (n=7) (n= 14) (n=5) (n=7)
Mg treatment significantly reduced IS independent of ita effects on hemo-
dynamics, andthiswasaboiishad by6PT. Thus weconcludethatendogenous
adenosine is at least in part responsible for the infarct size limiting effect of
Mg.
